ethyl 7-chloro-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate

‌Product Name‌: Ethyl 7-Chloro-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (Ozenoxacin Intermediate A)
‌CAS No.‌: 103877-51-6

🔬 ‌Product Overview‌
A key intermediate in the synthesis of ‌Ozenoxacin‌, a non-fluorinated quinolone antibacterial agent. This compound is essential for pharmaceutical manufacturers producing broad-spectrum antibiotics targeting skin infections like impetigo. With a purity of ‌≥99%‌ (HPLC), it ensures high-quality API production. Available in bulk quantities (1kg to 1000g) with stable inventory and prompt delivery.

📊 ‌Key Advantages‌
✅ ‌High Purity‌: ≥99% (HPLC/GC certified) for API compliance.
⚡ ‌Stable Supply‌: Multiple suppliers offer >1kg inventory with 2025 availability dates.
🔍 ‌Strict QC‌: Batch-specific COA, traceable synthesis pathways.

💊 ‌Applications‌

1. ‌Pharmaceutical Synthesis‌: Critical for manufacturing Ozenoxacin (CAS 245765-41-7), used in topical treatments for Staphylococcus aureus and Streptococcus pyogenes infections.

2. ‌R&D‌: Supports development of novel quinolone-based antimicrobials.

📜 ‌Quality Certification‌

• ‌Test Methods‌: HPLC, GC, NMR, and mass spectrometry.

• ‌Standards‌: Complies with ICH Q7 and ISO 9001 guidelines.

🌍 ‌Market Trends‌
The global demand for Ozenoxacin intermediates is rising due to expanding applications in dermatology and antibiotic resistance research. With Ozenoxacin’s patent expirations (2024-2034), generic drug production is projected to grow by ‌12% CAGR‌ (2025-2030). Strategic partnerships with certified suppliers ensure competitive pricing and scalability.